Christian Doppler Laboratory for Allergy Research, Vienna, Austria.
Allergy. 2011 Jun;66(6):775-83. doi: 10.1111/j.1398-9995.2011.02565.x. Epub 2011 Feb 26.
The broad applicability of allergen-specific immunotherapy for the treatment and eventually prevention of IgE-mediated allergy is limited by the poor quality and allergenic activity of natural allergen extracts that are used for the production of current allergy vaccines. Today, the genetic code of the most important allergens has been deciphered; recombinant allergens equalling their natural counterparts have been produced for diagnosis and immunotherapy, and a large panel of genetically modified allergens with reduced allergenic activity has been characterized to improve safety of immunotherapy and explore allergen-specific prevention strategies. Successful immunotherapy studies have been performed with recombinant allergens and hypoallergenic allergen derivatives and will lead to the registration of the first recombinant allergen-based vaccines in the near future. There is no doubt that recombinant allergen-based vaccination strategies will be generally applicable to most allergen sources, including respiratory, food and venom allergens and allow to produce safe allergy vaccines for the treatment of the most common forms of IgE-mediated allergies.
变应原特异性免疫疗法在 IgE 介导的过敏治疗和最终预防中的广泛适用性受到限制，原因是用于生产当前过敏疫苗的天然变应原提取物质量差且变应原活性低。如今，最重要的变应原的遗传密码已经被破译；已为诊断和免疫治疗生产出与天然变应原等同的重组变应原，并且已经对具有降低变应原活性的大量基因修饰变应原进行了表征，以提高免疫治疗的安全性并探索变应原特异性预防策略。使用重组变应原和低变应原性变应原衍生物进行了成功的免疫治疗研究，并将在不久的将来导致首批基于重组变应原的疫苗注册。毫无疑问，基于重组变应原的疫苗接种策略将普遍适用于大多数变应原来源，包括呼吸道、食物和毒液变应原，并允许生产用于治疗最常见 IgE 介导过敏形式的安全过敏疫苗。
